935 related articles for article (PubMed ID: 11721719)
1. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S
Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
[TBL] [Abstract][Full Text] [Related]
4. The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.
Lavi S; Gruberg L; Kapeliovich M; Hammerman H; Boulos M; Grenadier E; Aronson D; Markiewicz W; Beyar R
J Invasive Cardiol; 2005 Jun; 17(6):296-9. PubMed ID: 16003002
[TBL] [Abstract][Full Text] [Related]
5. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG
Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222
[TBL] [Abstract][Full Text] [Related]
6. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).
Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT
Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466
[TBL] [Abstract][Full Text] [Related]
7. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
[TBL] [Abstract][Full Text] [Related]
9. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
10. [The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].
Sarullo FM; Schicchi R; Schirò M; Americo L; Bonnì G; Faraone N; Di Pasquale P; Castello A; Mauri F
Ital Heart J Suppl; 2000 Jan; 1(1):81-7. PubMed ID: 10832123
[TBL] [Abstract][Full Text] [Related]
11. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.
Campbell KR; Ohman EM; Cantor W; Lincoff AM
Am J Cardiol; 2000 Apr; 85(8A):32C-8C. PubMed ID: 10793178
[TBL] [Abstract][Full Text] [Related]
12. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.
Maioli M; Zeymer U; van 't Hof AW; Gibson CM; Dudek D; Bellandi F; Noc M; Secco GG; Zorman S; Gabriel HM; Emre A; Cutlip D; Rakowski T; Gyongyosi M; Huber K; De Luca G;
J Invasive Cardiol; 2012 Jul; 24(7):324-7. PubMed ID: 22781470
[TBL] [Abstract][Full Text] [Related]
13. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
[TBL] [Abstract][Full Text] [Related]
14. Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.
Uyarel H; Uzunlar B; Unal Dayi S; Tartan Z; Samur H; Kasikcioglu H; Akgul O; Simsek D; Erdem I; Okmen E; Cam N
Cardiology; 2006; 105(3):168-75. PubMed ID: 16479104
[TBL] [Abstract][Full Text] [Related]
15. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
16. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
[TBL] [Abstract][Full Text] [Related]
17. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.
J Am Coll Cardiol; 1998 Dec; 32(7):2003-10. PubMed ID: 9857885
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
[TBL] [Abstract][Full Text] [Related]
19. Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.
De Luca G; Gibson MC; Hof AW; Cutlip D; Zeymer U; Noc M; Maioli M; Zorman S; Gabriel MH; Secco GG; Emre A; Dudek D; Rakowski T; Gyongyosi M; Huber K; Bellandi F;
J Cardiovasc Med (Hagerstown); 2013 Nov; 14(11):815-20. PubMed ID: 23519096
[TBL] [Abstract][Full Text] [Related]
20. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
